Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes. (Q38039980)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22941588%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

title

Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22941588%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

1 reference

1 reference

Marja-Riitta Taskinen

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22941588%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

Niina Matikainen

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22941588%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

language of work or name

1 reference

1 December 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22941588%20AND%20SRC:MED&resulttype=core&format=json

Current cardiology reports

12 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22941588%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22941588%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22941588%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

721-731

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22941588%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11886-012-0309-3

12 February 2020

exact match

0 references

cites work

Executive Summary: Heart Disease and Stroke Statistics--2012 Update: A Report From the American Heart Association

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Lipid control in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

HDL cholesterol protects against cardiovascular disease in both genders, at all ages and at all levels of risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Diabetic dyslipidaemia: from basic research to clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

A practical approach to the metabolic syndrome: review of current concepts and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Insulin resistance and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Major lipids, apolipoproteins, and risk of vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Meta-analysis of statin effects in women versus men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Implications from the Air Force/Texas Coronary Atherosclerosis Prevention Study for the Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prev

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Statins are diabetogenic--myth or reality?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Bezafibrate in men with lower extremity arterial disease: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Efficacy and safety of etofibrate in patients with non-proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Effects of combination lipid therapy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Combination lipid therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Do persons with diabetes benefit from combination statin and fibrate therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Fish oil and omega-3 fatty acids in cardiovascular disease: do they really work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Role of ω3 long-chain polyunsaturated fatty acids in reducing cardio-metabolic risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Triglycerides: a case for treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

The emerging role of HDL in glucose metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Healthy lifestyle through young adulthood and the presence of low cardiovascular disease risk profile in middle age: the Coronary Artery Risk Development in (Young) Adults (CARDIA) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Ideal cardiovascular health in childhood and cardiometabolic outcomes in adulthood: the Cardiovascular Risk in Young Finns Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

The biology and therapeutic targeting of the proprotein convertases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Gut-liver interaction in triglyceride-rich lipoprotein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Fatty acids, obesity, and insulin resistance: time for a reevaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Inhibition of hepatic sulfatase-2 in vivo: a novel strategy to correct diabetic dyslipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Rosuvastatin in older patients with systolic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Triglycerides and the Risk of Coronary Heart Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0309-3

Standards of medical care in diabetes--2012

21 January 2018

1 reference

12 December 2020

The link between metabolic abnormalities and endothelial dysfunction in type 2 diabetes: an update

1 reference

12 December 2020

Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study

1 reference

12 December 2020

Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980–2000

1 reference

12 December 2020

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

1 reference

12 December 2020

Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial

1 reference

12 December 2020

Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study

1 reference

12 December 2020

Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes

1 reference

12 December 2020

Endothelial dysfunction in type 2 diabetes

1 reference

12 December 2020

ESC/EAS Guidelines for the management of dyslipidaemias

1 reference

12 December 2020

Diabetic dyslipidaemia

1 reference

12 December 2020

Nonfasting Triglycerides and Risk of Myocardial Infarction, Ischemic Heart Disease, and Death in Men and Women

1 reference

12 December 2020

Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN)

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

1 reference

12 December 2020

Dual metabolic defects are required to produce hypertriglyceridemia in obese subjects

1 reference

12 December 2020

10.1007/S11886-012-0309-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22941588%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

12 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22941588%20AND%20SRC:MED&resulttype=core&format=json